[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anesthesia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anesthesia":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,196,0,25,[9,45,78,105,138,166,186,206,223,250,283,319,356,378,403,436,455,479,503,527,554,588,609,636,664],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642858","clinical-performance-and-multitasking-in-anesthesia--a-simulation-based-study-100642858",false,"NCT07615582","Clinical Performance and Multitasking in Anesthesia : a Simulation-based Study","FOCUS","Inclusion Criteria:\n\n* Anesthesiology and intensive care resident or attending physician\n* Written informed consent\n\nExclusion Criteria:\n\n* None",true,"ALL","18 Years",{"count":21,"type":22},35,"ESTIMATED","OBSERVATIONAL","Cognitive failure under multitasking conditions has been demonstrated in various settings, including healthcare. However, in anesthesiology, the impact of multitasking on clinical performance has not yet been fully characterized.\n\nThe objective of our study is to evaluate the impact of multitasking on anesthesiologists' clinical performance in a simulated setting.",[26,27,28,29,30,31],"Multitasking Behavior and Multitasking Ability","Clinical Performance","Simulation Training","Simulation Based Medical Education","Clinical Reasoning","Anesthesia","RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2026-06-09",{"date":40,"type":22},"2026-12",{"name":42,"class":43},"University Hospital, Grenoble","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":44},"100635864","multimodal-anesthesia-in-robotic-laparoscopic-nephrectomy-100635864","NCT07558226","Multimodal Anesthesia in Robotic Laparoscopic Nephrectomy","Efficacy of Multimodal Anesthesia in Robotic Laparoscopic Nephrectomy: Impact on Recovery and Early Hospital Discharge.","MANTRA","Inclusion Criteria:\n\n* Patients ≥18 years.\n* Indication for elective oncological robotic partial or radical nephrectomy.\n* ASA classification I-III.\n* Candidates for short-stay surgery according to institutional protocol.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Chronic opioid use. Defined as continuous opioid use during the 3 months prior to surgery\n* Uncontrolled chronic pain. Defined as chronic pain not adequately controlled with usual treatment during the 3 months prior to surgery.\n* Contraindications to NSAIDs, regional anesthesia, or drugs of the multimodal protocol.\n* Advanced renal failure (GFR \\\u003C30 ml\u002Fmin) at the preanesthetic visit.",{"count":54,"type":22},80,"INTERVENTIONAL",[57],"NA","It is a prospective, randomized, controlled and superiority clinical trial, with the objective of comparing the effectiveness of multimodal anesthesia versus conventional anesthesia in patients undergoing oncological robotic nephrectomy within a short-stay surgery program (SSA). The effect of no specific drug will be evaluated, but rather the anesthetic approach ologies of surgical patients. The clinical trial will be carried out in a third-level university hospital, between the first half of 2026 and the second half of 2027 and, after approval by the corresponding Clinical Research Ethics Committee.",[31,60,61],"Anesthesia and Procedure Related Time Intervals","Nephrectomy \u002F Methods",[63,64,65,31,66,67,68],"laparoscopic nephrectomy robotic","multimodal anesthesia","early hospital discharge","Multimodal","Nephrectomy","Robotic","2026-06-29",{"date":71,"type":36},"2026-07-01",{"date":73,"type":36},"2026-05-02",{"date":75,"type":22},"2027-11-30",{"name":77,"class":43},"Fundacio Puigvert",{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":17,"sex":18,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":55,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":44},"100486865","phase-1-oral-dexmedetomidine-in-pediatric-mri-100486865","NCT05619627","Oral Dexmedetomidine in Pediatric MRI","Utility of Oral Dexmedetomidine as the Sole Sedative Agent in Pediatric Population Undergoing MRI","Inclusion Criteria:\n\n1. Participants 3-6 years old, male and female, all races and ethnicities\n2. Requiring a clinically indicated MRI with general anesthesia\n\nExclusion Criteria:\n\n1. Refusal to take oral dexmedetomidine\n2. Known allergy to dexmedetomidine\n3. Inability to take dexmedetomidine at least 90 minutes prior to start of the MRI\n4. Medical contraindications to administration of dexmedetomidine including:\n\n   1. Unstable cardiac status including life threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction\n   2. Current use of digoxin\n   3. Moya Moya disease\n   4. New onset stroke\n5. American Society of Anesthesiologists (ASA) physical status classification \\> II\n6. Contraindications to administering sedation including:\n\n   1. Active and uncontrolled gastroesophageal reflux\n   2. Active and uncontrolled vomiting\n   3. Current or recent history of apnea\n   4. Active respiratory disease including pneumonia, bronchitis, respiratory syncytial virus infection, asthma exacerbation\n   5. Craniofacial anomalies\n7. Inability to have MRI scans\n8. Non-English speaking volunteers","3 Years","6 Years",{"count":88,"type":22},18,[90],"PHASE1","The objective of this preliminary study is to assess the utility of oral dexmedetomidine as the sole sedative agent in pediatric population undergoing MRI.",[31],[94],"Oral dexmedetomidine","NOT_YET_RECRUITING","2026-06-24",{"date":98,"type":36},"2026-06-25",{"date":100,"type":22},"2026-08-01",{"date":102,"type":22},"2027-12",{"name":104,"class":43},"Soroush Merchant",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":114,"conditions":115,"keywords":130,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":135,"leadSponsor":136,"locationsCount":44},"100642312","risk-factors-of-atrial-fibrillation-after-cardiac-surgery-100642312","NCT07625033","Risk Factors of Atrial Fibrillation After Cardiac Surgery","PFAS","Inclusion Criteria:\n\n* age \\>18\n* having undergone a scheduled cardiac surgery in the study center\n* having agreed to the reuse of their hospital care data\n\nExclusion Criteria:\n\n* Atrial fibrillation at the admission in hospital.",{"count":113,"type":22},918,"Supraventricular arrhythmias complicate more than 40% of cardiac surgeries and are associated with an increased risk of bleeding, stroke, heart failure, and death. Preventing the occurrence of these arrhythmias is a major challenge. This study aims to investigate risk factors and protective factors regarding atrial fibrillation and other iatrogenic cardiac arrhythmias after cardiac surgery, particularly innovative anesthetic strategies such as stellar ganglion blockade which have been recently implemented in our center.",[116,117,118,119,120,121,122,123,124,125,126,127,31,128,129],"Cardiac Surgery","Peri Operative Medicine","Thoracic Surgery","Cardiopulmonary Bypass","Coronary Artery Bypass","Heart Valve Prosthesis Implantation","Aortic Valve Replacement","Perioperative Medicine","Preoperative Care","Intraoperative Care","Postoperative Care","Enhanced Recovery After Surgery","Cardiac Anesthesia","Intensive Care Unit",[131],"Stellar Ganglion Blockade, SGB, cardiac surgery","2026-06-23",{"date":98,"type":36},{"date":71,"type":22},{"date":71,"type":22},{"name":137,"class":43},"Centre Hospitalier Régional Metz-Thionville",{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":55,"phases":148,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":44},"100642256","phase-4-oliceridine-vs-sufentanil-for-cough-during-anesthesia-induction-100642256","NCT07660380","Oliceridine vs Sufentanil for Cough During Anesthesia Induction","Oliceridine vs Sufentanil for Cough During General Anesthesia Induction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 99 years.\n* American Society of Anesthesiologists (ASA) physical status classification I, II, or III.\n* Body mass index (BMI) between 18.5 and 28.0 kg\u002Fm².\n* Scheduled for elective surgery under general anaesthesia.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative upper respiratory tract infection symptoms (e.g., cough, expectoration, or fever) or a history of bronchial asthma or other conditions associated with increased airway reactivity.\n* Severe cardiovascular disease (e.g., uncontrolled hypertension, recent myocardial infarction, or serious arrhythmia) or hepatic or renal dysfunction.\n* Long-term opioid use, defined as continuous opioid use for more than 2 weeks within the 3 months prior to surgery.\n* Known hypersensitivity to any study drug or anaesthetic agent used in this protocol.\n* Anticipated difficult airway requiring awake intubation.\n* Pregnancy or breastfeeding.","99 Years",{"count":147,"type":22},62,[149],"PHASE4","Sufentanil is the most widely used opioid analgesic for general anaesthesia induction; however, rapid intravenous bolus injection frequently triggers sufentanil-induced cough (SIC). In high-risk patients, SIC can cause abrupt elevation of intracranial and intraocular pressure and severe haemodynamic instability, posing a meaningful safety risk during the induction period.\n\nOliceridine, the first G protein-biased μ-opioid receptor agonist approved by the Food and Drug Administration in 2020, provides analgesia through μ-receptor activation while substantially reducing β-arrestin-2 recruitment. This biased signalling profile is hypothesised to raise the excitation threshold of airway C-fibres and thereby reduce the incidence of cough.\n\nThis prospective, single-centre, randomised, double-blind, parallel-group controlled trial directly compares oliceridine with sufentanil for general anaesthesia induction with respect to cough incidence, cough severity, haemodynamic responses, and perioperative safety, with the aim of providing evidence-based guidance for opioid selection during induction.",[152,31],"Cough",[154,155,156,157,158],"Oliceridine","Sufentanil","Sufentanil-induced cough","G protein-biased agonist","Anesthesia induction","2026-06-18",{"date":132,"type":36},{"date":162,"type":22},"2026-06-22",{"date":71,"type":22},{"name":165,"class":43},"Shiyou Wei",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":55,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":44},"100642251","cerebral-oximetry-guided-low-fio2-strategies-in-thoracic-surgery-100642251","NCT07659483","Cerebral Oximetry-Guided Low FiO2 Strategies in Thoracic Surgery.","Safety and Efficacy of Cerebral Oximetry-Guided Low FiO2 Strategies in Thoracic Surgery","Inclusion Criteria:\n\n* Patients aged 18 years or older. Scheduled for elective thoracic surgery requiring one-lung ventilation (OLV). American Society of Anesthesiologists (ASA) Physical Status classification I-III.\n\nExclusion Criteria:\n\n* History of cerebrovascular disease. Left ventricular ejection fraction Pulmonary hypertension. Interstitial lung disease.\n\nRenal failure. Neuromuscular disease. Pregnancy. Expected OLV duration less than 30 minutes (\\\u003C 30 min)",{"count":174,"type":22},60,[57],"Brief Summary (Kısa Özet)The purpose of this study is to evaluate the safety and efficacy of a cerebral oximetry-guided low fraction of inspired oxygen (FiO\\_2) ventilation strategy compared to a standard high FiO\\_2 strategy in patients undergoing elective thoracic surgery requiring one-lung ventilation (OLV).Oxygen toxicity and related postoperative pulmonary complications remain significant risks during thoracic anesthesia. While standard protocols often rely on high inspired oxygen concentrations to maintain peripheral oxygen saturation (SpO\\_2), this approach may induce hyperoxia. Conversely, lowering FiO\\_2 arbitrarily can increase the risk of hypoxemia or compromise tissue oxygenation. This prospective, parallel-group, 1:1 randomized, single-blind clinical trial aims to safely reduce intraoperative oxygen exposure by using regional cerebral oxygen saturation (rSO\\_2) monitoring as a physiological guide.A total of 60 participants aged 18 and older, classified as ASA I-III and scheduled for elective thoracic surgery, will be randomly assigned to one of two arms:Experimental Group (Guided Low FiO\\_2 Strategy): Ventilation will be initiated at a low FiO\\_2 of 0.5. The FiO\\_2 level will not be increased unless peripheral saturation (SpO\\_2) falls below 90% or cerebral oxygenation (rSO\\_2) drops below 80% of the patient's baseline value.Active Comparator Group (Standard Strategy): Patients will receive conventional anesthesia management, maintaining standard high FiO\\_2 levels to keep SpO\\_2 above 90% without cerebral oximetry guidance.The primary outcomes to be measured are the incidence of cerebral desaturation during the perioperative period and the incidence of postoperative delirium assessed via the 3D-CAM tool until hospital discharge. Secondary outcomes include intraoperative hemodynamic stability, arterial blood gas parameters (PaO\\_2, PaCO\\_2, pH, lactate), incidence of hypoxemia, total one-lung ventilation duration, postoperative cognitive dysfunction (POCD), and lengths of stay in both the intensive care unit (ICU) and the hospital.By utilizing real-time non-invasive cerebral oximetry, the study intends to demonstrate a safe ventilation protocol that minimizes oxygen toxicity without compromising cerebral oxygenation or clinical recovery outcomes.",[118,31],"2026-06-16",{"date":162,"type":36},{"date":181,"type":22},"2026-06-15",{"date":183,"type":22},"2026-08-15",{"name":185,"class":43},"Dicle University",{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":55,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100642447","remifentanil-vs-nicardipine-for-controlled-hypotension-in-elective-nasal-surgery-100642447","NCT07660562","Remifentanil vs. Nicardipine for Controlled Hypotension in Elective Nasal Surgery","Comparison of Remifentanil and Nicardipine Infusions for Controlled Hypotension in Elective Nasal Surgery Where Bleeding Control is Critical: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\> 18 years\n* ASA physical status I-II\n* Scheduled for elective nasal surgery\n* No known serious cardiovascular, respiratory, renal, or hepatic disease\n* No known allergy to remifentanil or nicardipine\n* No chronic use of beta-blockers, calcium channel blockers, or antihypertensive agents\n* Not pregnant or breastfeeding\n* BMI ≤ 35 kg\u002Fm²\n* No emergency surgical indication\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* ASA III or above\n* Known serious cardiovascular, respiratory, renal, or hepatic disease\n* Known allergy to remifentanil or nicardipine\n* Chronic use of beta-blockers, calcium channel blockers, or antihypertensive agents\n* Pregnancy or breastfeeding\n* Morbid obesity (BMI \\> 35 kg\u002Fm²)\n* Emergency surgery\n* Refusal to participate",{"count":194,"type":22},44,[57],"This study compares remifentanil infusion versus nicardipine infusion for controlled hypotension during elective nasal surgery. Both agents are standard clinical methods. The study evaluates hemodynamic stability, surgical field quality (Fromme-Boezaart score), tissue perfusion, intraoperative blood loss, surgeon satisfaction, and perioperative adverse effects.",[198,31,199],"Nasal Surgery","Controlled Hypotension for Nasal Surgeries",{"date":162,"type":36},{"date":98,"type":22},{"date":203,"type":22},"2026-07-15",{"name":205,"class":43},"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":55,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":220,"leadSponsor":222,"locationsCount":44},"100642156","remifentanil-monotherapy-vs-remifentanil-nicardipine-for-controlled-hypotension-in-otolaryngological-surgery-100642156","NCT07659496","Remifentanil Monotherapy vs. Remifentanil-Nicardipine for Controlled Hypotension in Otolaryngological Surgery","The Effects of Remifentanil Monotherapy Versus Remifentanil-Nicardipine Combination on Advanced Hemodynamic Parameters for Controlled Hypotension During Otolaryngological Surgery","Inclusion Criteria:\n\n* Patients aged \\> 18 years\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Scheduled to undergo otolaryngological surgery under general anesthesia\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Aged \\\u003C 18 years\n* ASA physical status III or higher\n* Known severe cardiovascular (coronary artery disease, heart failure, uncontrolled hypertension), respiratory, renal, or hepatic disease\n* Known allergy to the study drugs (remifentanil, nicardipine)\n* Chronic use of beta-blockers, calcium channel blockers, or any other medication affecting blood pressure\n* Pregnancy or breastfeeding\n* Morbid obesity\n* Emergency surgery requirement\n* Refusal to participate in the study",{"count":174,"type":22},[57],"Controlled hypotension is a widely employed technique in otolaryngological (ear, nose, and throat) surgery, primarily aimed at improving surgical field visibility and minimizing intraoperative blood loss. By maintaining mean arterial pressure within a targeted range, this approach facilitates a clearer operative field, reduces the need for blood transfusion, and shortens operative time, thereby contributing to improved surgical outcomes.\n\nAmong the pharmacological agents used to achieve controlled hypotension, remifentanil - an ultra-short-acting synthetic opioid - has gained widespread acceptance due to its rapid onset, predictable offset, and favorable hemodynamic profile. Nicardipine, a second-generation dihydropyridine calcium channel blocker, is also utilized for its potent vasodilatory properties and titratable antihypertensive effect. When used in combination, these two agents may offer complementary mechanisms of action; however, their combined impact on advanced hemodynamic parameters remains insufficiently characterized in the otolaryngological surgical setting.\n\nThe primary aim of this study is to compare the effects of remifentanil monotherapy versus remifentanil-nicardipine combination therapy on advanced hemodynamic parameters, cardiac physiology, and tissue perfusion in patients undergoing controlled hypotension during otolaryngological surgery. Advanced hemodynamic monitoring - including parameters such as cardiac output, stroke volume, systemic vascular resistance, and oxygen delivery indices - will provide a more comprehensive physiological assessment beyond conventional blood pressure measurements.\n\nAs secondary objectives, this study will evaluate and compare both regimens with respect to surgical field quality, surgeon satisfaction, intraoperative hemodynamic stability, and perioperative adverse effects. It is anticipated that a thorough comparative analysis of these two approaches will contribute to evidence-based anesthetic decision-making and help optimize patient safety and surgical outcomes in otolaryngological procedures.",[217,31],"Otolaryngological Surgery",{"date":162,"type":36},{"date":33,"type":22},{"date":221,"type":22},"2026-08-30",{"name":185,"class":43},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":230,"minAge":19,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":55,"phases":232,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":249},"100642494","spinal-versus-general-anesthesia-in-open-simple-prostatectomy-100642494","NCT07643415","Spinal Versus General Anesthesia in Open Simple Prostatectomy","Effect of Spinal Versus General Anesthesia on Postoperative Bleeding in Patients Undergoing Open Simple Prostatectomy: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 18 years or older.\n* Diagnosis of benign prostatic hyperplasia (BPH).\n* Scheduled to undergo open simple prostatectomy.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.\n* Patients scheduled for radical prostatectomy due to prostate cancer.\n* Emergency surgery.\n* Known coagulation disorders or clinically significant thrombocytopenia.\n* Ongoing anticoagulant or antiplatelet therapy that cannot be discontinued according to institutional protocols.\n* Contraindication to spinal anesthesia.\n* Participation in another interventional clinical trial that may affect study outcomes.\n* Administration of tranexamic acid or any additional hemostatic agent during the perioperative period.","MALE",{"count":54,"type":22},[57],"Open simple prostatectomy is still performed for selected patients with benign prostatic hyperplasia, particularly in cases with large prostate volume. Postoperative bleeding, hematuria, clot retention, and transfusion requirement are clinically important complications after this procedure.\n\nThis prospective randomized controlled trial will compare the effects of spinal anesthesia and general anesthesia on postoperative bleeding in patients undergoing open simple prostatectomy. Participants will be randomized into two groups: spinal anesthesia or general anesthesia. Tranexamic acid or any additional hemostatic agent will not be used. Postoperative bleeding will be assessed using hemoglobin and hematocrit changes, transfusion requirement, hematuria, clot retention, need for bladder irrigation, and bleeding-related reintervention.\n\nThe study aims to determine whether spinal anesthesia is associated with reduced postoperative bleeding compared with general anesthesia in open simple prostatectomy.",[235,236,31],"Urologic Neoplasms","Benign Prostatic Hyperplasia",[238,239,240,241],"Open simple prostatectomy","Spinal anesthesia","general anesthesia","postoperative bleeding",{"date":178,"type":36},{"date":244,"type":36},"2026-04-29",{"date":246,"type":22},"2026-09-15",{"name":248,"class":43},"Hitit University",2,{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":55,"phases":260,"briefSummary":261,"conditions":262,"keywords":266,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":44},"100642020","qr-code-based-video-supported-anesthesia-information-and-preoperative-anxiety-100642020","NCT07647588","QR Code-Based Video-Supported Anesthesia Information and Preoperative Anxiety","The Effect of QR Code-Based Video-Supported Anesthesia Information on Preoperative Anxiety, Comprehensibility of Information, and Patient Satisfaction: A Prospective Randomized Controlled Study","QR-AID","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled for elective surgery\n* Evaluated in the anesthesia outpatient clinic\n* Able to understand the study information and questionnaires\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Emergency surgery\n* Impaired consciousness\n* Advanced dementia\n* Severe psychiatric illness\n* Severe visual, hearing, or cognitive impairment\n* Inability to understand the digital educational content\n* Refusal to participate\n* Inability to read or understand Turkish",{"count":259,"type":22},284,[57],"This study aims to evaluate the effects of QR code-based video-supported anesthesia information on preoperative anxiety, comprehensibility of information, and patient satisfaction in adult patients undergoing elective surgery.\n\nParticipants will be randomly assigned in a 1:1 ratio to either a control group receiving standard written informed consent and routine verbal anesthesia information or an intervention group receiving the same standard information plus a standardized video-based educational intervention accessed through a QR code.\n\nThe primary outcome is the change in the Amsterdam Preoperative Anxiety and Information Scale (APAIS) anxiety score before and after the information process. Secondary outcomes include comprehensibility of information and patient satisfaction assessed using a structured Likert-type questionnaire.\n\nThe findings may contribute to the standardization of patient information processes in anesthesia outpatient clinics through a low-cost and easily implementable digital educational approach.",[263,31,264,265],"Preoperative Anxiety","Informed Consent","Patient Education",[267,268,269,270,271,272,264,273,274,263],"QR Code","Video-Supported Education","Amsterdam Preoperative Anxiety and Information Scale","APAIS","Anesthesia Information","Patient Satisfaction","Randomized Controlled Trial","Digital Health","2026-06-13",{"date":178,"type":36},{"date":278,"type":22},"2026-06-10",{"date":280,"type":22},"2026-07-10",{"name":282,"class":43},"Elazıg Fethi Sekin Sehir Hastanesi",{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":18,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":55,"phases":294,"briefSummary":295,"conditions":296,"keywords":304,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":44},"100431190","phase-4-opioid-free-anesthesia-analgesia-strategy-and-surgical-stress-in-elective-open-abdominal-aortic-aneurysm-repair-100431190","NCT04894864","Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair","Effect of a Perioperative Opioid Free Anesthesia-Analgesia (OFA-A) Strategy on Surgical Stress Response in Elective Open Abdominal Aortic Aneurysm Repair: A Prospective Randomized Study","Inclusion Criteria:\n\n1. Patient Consent\n2. Age between 40 and 85 years old\n3. Patients undergoing Elective Open Abdominal Aortic Infrarenal Aneurysm Repair\n\nExclusion Criteria:\n\n1. Immunocompromised patients\n2. Patients with active infection\n3. Reoperation on the aorta\n4. Inflammatory bowel Disease\n5. Malignancy\n6. Chronic Inflammatory conditions (e.g. Rheymatoid arthritis, Psoriatic arthritis)\n7. Chronic corticosteroid or immunosuppressive drug use\n8. Intraoperative transfusion with \\>2 units of packed Red Blood Cells","40 Years","85 Years",{"count":293,"type":22},40,[149],"Open Abdominal Aortic Aneurysm (AAA) repair is a high-risk surgical procedure accompanied by intense endocrine and metabolic responses to surgical stress, with subsequent activation of the inflammatory cascade, cytokine and acute-phase protein release, and bone marrow activation. There is a proven correlation of surgical stress, which patients undergoing open AAA repair are subjected to, with patient outcome, morbidity\u002Fmortality, intensive care unit stay and overall length of stay. Modern general anesthetic techniques have been revised and rely on perioperative multimodal anesthetic and analgesic strategies for improved overall patient outcome. Based on this context of a multimodal anesthetic technique and having taken into consideration the international \"opioid-crisis\" epidemic, an Opioid Free Anesthesia-Analgesia (OFA-A) strategy started to emerge. It is based on the administration of a variety of anesthetic\u002Fanalgesic agents with different mechanisms of action, including immunomodulating and anti-inflammatory effects.\n\nOur basic hypothesis is that the implementation of a perioperative multimodal OFA-A strategy, involving the administration of pregabalin, ketamine, dexmedetomidine, lidocaine, dexamethasone, dexketoprofen, paracetamol and magnesium sulphate, will lead to attenuation of surgical stress response compared to a conventional Opioid-Based Anesthesia-Analgesia (OBA-A) strategy. Furthermore, the anticipated attenuation of the inflammatory response, is pressumed to be associated with equal or improved analgesia, compared to a perioperative OBA-A technique.",[297,298,31,299,300,301,302,303],"Elective Surgical Procedures","Postoperative Pain","Opioid Use","Abdominal Aortic Aneurysm Without Rupture","Vascular Surgical Procedure","Interleukin 6","Immunomodulators",[305,306,307,308,309,310,311],"Opioid-free Anesthesia-Analgesia","Cytokines","Opioid-based Anesthesia-Analgesia","Haemodynamic Stability","Open Abdominal Aortic Aneurysm Repair","Immunomodulation","Inflammatory Markers",{"date":178,"type":36},{"date":314,"type":36},"2020-10-08",{"date":316,"type":22},"2027-09-01",{"name":318,"class":43},"University of Crete",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":327,"targetDuration":329,"studyType":23,"phases":4,"briefSummary":330,"conditions":331,"keywords":335,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":44},"100641518","prospective-multicentre-observational-registry-of-peri-procedural-anaesthesia-sedation-and-related-medication-exposure-in-patients-with-brugada-syndrome-100641518","NCT07655102","Prospective Multicentre Observational Registry of Peri-procedural Anaesthesia, Sedation and Related Medication Exposure in Patients With Brugada Syndrome","BRUGADA-ANAESTHESIA Registry: Prospective Multicentre Observational Registry of Peri-procedural Anaesthesia, Sedation and Related Medication Exposure in Patients With Brugada Syndrome","PROSP_BRUGANAE","Patients should match all the inclusion criteria to be entered for data collection:\n\n* Documented type 1 Brugada ECG pattern (spontaneous, fever-related, or induced by sodium-channel blocker challenge\u002Fother recognised provocation test) with a diagnosis considered compatible with Brugada syndrome by the treating cardiology team.\n* Undergoing general anaesthesia, monitored sedation, loco-regional anaesthesia for any surgical, diagnostic, interventional, obstetric or other non-surgical procedure (including epidural analgesia for labour and sedation for endoscopy).\n\nPatients with one or more exclusion criteria will not be included for data collection and analysis:\n\n* No documented type 1 Brugada ECG pattern, uncertain diagnosis without sufficient supporting data.\n* Refusal to participate in the study.",{"count":328,"type":22},200,"30 Days","The goal of this observational study is to evaluate the perioperative risk of malignant ventricular arrhythmias in adult patients diagnosed with Brugada Syndrome undergoing anaesthetic procedures. Brugada Syndrome is a rare inherited cardiac condition associated with an increased risk of life-threatening arrhythmias, and perioperative management remains challenging due to limited high-quality evidence.\n\nThe main questions it aims to answer are:\n\n* What is the incidence of malignant ventricular arrhythmias during anaesthesia and up to 30 days after the procedure?\n* Are anaesthetic drugs traditionally considered \"non-recommended\" associated with an increased risk of perioperative arrhythmic events?\n\nResearchers will also explore the relative contribution of anaesthetic drugs versus perioperative physiological factors (e.g., haemodynamic changes, fever, bradycardia) in triggering arrhythmias.\n\nParticipants will:\n\n* Undergo anaesthetic procedures (general, locoregional, or sedation) as part of routine clinical care\n* Have clinical data collected prospectively from electronic medical records during the perioperative period\n* Be followed for 30 days after the procedure to assess outcomes, including arrhythmias, complications, ICU admission, and mortality\n\nThis is a multicentre, prospective observational registry, and no additional interventions or changes to standard clinical practice will be performed.",[332,333,31,334],"Brugada Syndrome (BrS)","Ventricular Arrhythmia","Sedation",[336,337,31,338,339,340,341,342,343,344,345,346],"Brugada Syndrome","Anaesthesia","Perioperative Care","Ventricular Arrhythmias","Cardiac Arrhythmias","Perioperative Risk","Anesthetic Drugs","Propofol","Sodium Channel Blockers","Observational Registry","Multicentre Study","2026-06-12",{"date":349,"type":36},"2026-06-17",{"date":351,"type":22},"2026-07-20",{"date":353,"type":22},"2028-12-20",{"name":355,"class":43},"Hospital Clinic of Barcelona",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":55,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":374,"leadSponsor":376,"locationsCount":44},"100642345","efficacy-and-safety-of-the-visual-bronchial-blocker-for-lung-isolation-surgery-100642345","NCT07644104","Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation Surgery","Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation Surgery: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* ASA physical status I-III\n* Scheduled for elective thoracic surgery (pulmonary, esophageal, or mediastinal procedures) requiring one-lung ventilation and lung isolation\n* Able to understand and sign the informed consent form\n\nExclusion Criteria:\n\n* Anatomical abnormalities of the tracheobronchial tree, including anomalous right upper lobe bronchial origin, severe airway stenosis, or distortion\n* Planned bronchial sleeve resection or carinal surgery\n* Empyema, bronchopleural fistula, or severe pleural adhesions affecting bronchial anatomy\n* Previous thoracic surgery that altered bronchial anatomy\n* Severe cardiopulmonary dysfunction with a metabolic equivalent (MET) \\\u003C 4\n* Severe psychiatric disorders or inability to cooperate with anesthesia procedures\n* Current participation in another interventional clinical trial\n* Contraindications to bronchial blocker placement (e.g., known allergy to materials used, high risk of airway trauma)",{"count":364,"type":22},652,[57],"This multicenter, prospective, randomized, controlled clinical trial is initiated by the First Affiliated Hospital of Zhejiang University School of Medicine, with participation from Peking Union Medical College Hospital, the Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, and Shanxi Bethune Hospital. The study aims to compare the first-attempt placement success rate between visual bronchial blockers (VBB, test group) and conventional bronchial blockers (CBB, control group) during anesthesia for thoracic surgery, and to evaluate operational efficiency, lung isolation quality, and safety profiles.\n\nA total of 652 patients aged ≥18 years with ASA physical status I-III, scheduled for elective pulmonary, esophageal, or mediastinal surgery requiring lung isolation, will be enrolled in a 1:1 ratio (326 per group), with a 10% anticipated dropout rate. Key exclusion criteria include anomalous right upper lobe bronchial origin, severe airway anatomical abnormalities, bronchial sleeve resection, empyema, bronchopleural fistula, previous thoracic surgery altering bronchial anatomy, severe cardiopulmonary dysfunction (metabolic equivalent \\\u003C4), severe psychiatric disorders, and concurrent participation in other clinical trials.\n\nFollowing standardized anesthesia induction with rocuronium (2-3 × ED95), patients undergo tracheal intubation using a video laryngoscope. In the CBB group, placement is guided by blind probing and auscultation, with confirmation via fiberoptic bronchoscopy (FOB). In the VBB group, placement is performed under direct vision using the integrated camera, with FOB rescue allowed only if visualization fails (rescue cases are counted as failures). Placement success is defined as the cuff located in the ipsilateral main bronchus with the proximal cuff edge immediately below the carina.\n\nPrimary endpoint: First-attempt placement success rate. Secondary endpoints: Time to successful first placement, lung collapse grade (Likert 3-point scale), cumulative number and duration of FOB use, intraoperative blocker displacement, hypoxemia (SpO₂ \\\u003C90% or \\\u003C85% for ≥5 seconds), airway injury, hemodynamic changes, postoperative sore throat, hoarseness, hospital length of stay, ICU admission rate, postoperative pulmonary complications, and 30-day all-cause mortality. Operator and surgeon satisfaction will be rated on a 0-10 scale.\n\nRandomization is centralized, stratified by center, using variable block sizes (4, 6, or 8) to ensure allocation concealment. Outcome assessors and patients are blinded to group assignment, while operators are not. An independent Endpoint Adjudication Committee will review imaging data for blinded verification.\n\nStatistical analysis will be performed using SPSS 27.0 and R software. Baseline characteristics will be compared using independent samples t-test, Mann-Whitney U test, chi-square test, or Fisher's exact test as appropriate. The primary endpoint (binary variable) will be analyzed using generalized linear mixed models (GLMM) with center as a random effect and logistic regression as a sensitivity analysis. A two-sided P\\\u003C0.05 is considered statistically significant. Full Analysis Set (intention-to-treat), Per-Protocol Set, and Safety Set will be defined for efficacy and safety evaluations.\n\nThe trial timeline includes registration and training (June 2026 - August 2026), patient recruitment and data collection (September 2026 - September 2027), and data analysis, manuscript preparation, and publication (October 2027 - Dec 2028). Adverse events will be monitored, documented, and reported in accordance with CTCAE v5.0; serious adverse events will be reported to the ethics committee within 24 hours.\n\nThis study is the first randomized controlled trial evaluating a visual bronchial blocker worldwide. The investigators hypothesize that VBB improves first-attempt placement success, shortens positioning time, reduces FOB reliance, enhances lung collapse quality, decreases intraoperative displacement and hypoxemia, and lowers airway injury and postoperative complications. The results will provide high-level evidence for the clinical application of VBB in thoracic anesthesia and promote the visualization and standardization of one-lung ventilation techniques.",[368,369,370,31],"Thoracic Surgery With One-lung Ventilation","Lung Isolation","Bronchial Blockage","2026-06-11",{"date":347,"type":36},{"date":100,"type":22},{"date":375,"type":22},"2027-12-31",{"name":377,"class":43},"Zhejiang University",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":385,"enrollmentInfo":386,"targetDuration":4,"studyType":55,"phases":388,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":399,"leadSponsor":401,"locationsCount":44},"100643016","phase-4-the-effects-of-different-anesthetics-on-the-brains-neural-networks-100643016","NCT07644663","The Effects of Different Anesthetics on the Brain's Neural Networks","Propofol, Dexmedetomidine, and Esketamine-Induced Unresponsive States: Alterations in Information Integration and Brain Networks","Inclusion Criteria:\n\n* Patients scheduled for elective non-cardiac surgery;\n* American Society of Anesthesiologists (ASA) physical status classification I-II;\n* Aged 18 to 65 years, regardless of gender;\n* Body mass index (BMI) greater than 18 kg\u002Fm² and no more than 31 kg\u002Fm²;\n* Written informed consent voluntarily signed by the patient or legal authorized representative for participation in this study.\n\nExclusion Criteria:\n\nSubjects meeting any one of the following items will be excluded from this study:\n\n* Presence of severe cardiovascular diseases or hepatic and renal insufficiency;\n* Hearing impairment;\n* History of psychiatric disorders or communication disorders;\n* Anticipated difficult airway;\n* Pregnant or lactating women;\n* History of allergic reaction or contraindication to any of the three anesthetic drugs used in this trial;\n* Participation in other clinical trials within the past 3 months.","65 Years",{"count":387,"type":22},120,[149],"This study aims to analyze the electroencephalographic power spectrum and connectivity during unresponsive states induced by propofol, esketamine and dexmedetomidine, respectively. It intends to explore the macro neural mechanisms underlying anesthetic unresponsiveness, so as to further elucidate the mechanisms by which anesthetics induce loss and recovery of consciousness. In addition, this study will identify neural biomarkers under general anesthesia for monitoring patients' actual intraoperative consciousness status. The findings will facilitate the development of monitoring indicators and devices reflecting intraoperative consciousness during general anesthesia, enabling more accurate assessment of patients' intraoperative consciousness status.",[391,31],"Electroencephalogram (EEG)",[393,394,395],"EEG","anesthesia","loss of responsiveness","2026-06-08",{"date":347,"type":36},{"date":38,"type":22},{"date":400,"type":22},"2026-09-10",{"name":402,"class":43},"Fudan University",{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":411,"maxAge":412,"enrollmentInfo":413,"targetDuration":415,"studyType":23,"phases":4,"briefSummary":416,"conditions":417,"keywords":420,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":249},"100642003","transition-from-sevoflurane-to-total-intravenous-anesthesia-in-pediatric-patients-100642003","NCT07644260","Transition From Sevoflurane to Total Intravenous Anesthesia in Pediatric Patients","Observational Analysis of the Transition From Inhalational Anesthesia to Total Intravenous Anesthesia Guided by Bispectral Index and the Eleveld Model in Pediatric Patients","TSTP","Inclusion Criteria:\n\n* Age 2 to 12 years\n* Scheduled for elective low- or intermediate-risk surgery according to the National Institute for Health and Care Excellence (NICE) surgical risk stratification (e.g., tonsillectomy, adenoidectomy, postioplasty, orchidectomy, orchidopexy, inguinal herniorrhaphy)\n* American Society of Anesthesiologists (ASA) Physical Status Classification I or II\n\nExclusion Criteria:\n\n* Refusal of parents\u002Flegal guardians to sign informed consent, or refusal of the child to provide assent when applicable\n* Cardiovascular or neurological disease that may interfere with anesthesia or with the pharmacokinetic model\n* History of allergy or adverse reaction to inhalational or intravenous anesthetic agents used in the protocol\n* Airway malformations or conditions that complicate standard intubation or airway management\n* Psychological or neurological conditions requiring sedative or hypnotic premedication prior to the anesthetic procedure\n* Treatment with drugs that may alter the pharmacokinetics or pharmacodynamics of the anesthetic agents\n* Difficult peripheral venous access","2 Years","12 Years",{"count":414,"type":22},50,"1 Day","his prospective, observational, exploratory, and multicenter study aims to describe the evolution of propofol effect-site concentration administered via target-controlled infusion (TCI) based on the Eleveld model-with adjustments for opioid co-administration-guided by the bispectral index (BIS) during the transition from inhalational anesthesia with sevoflurane to total intravenous anesthesia (TIVA) in pediatric patients.The study population will include 50 pediatric patients, aged 2 to 12 years, scheduled for elective low- or medium-complexity surgeries. Induction will be performed with sevoflurane, followed by intravenous access placement and transition to TIVA using propofol and remifentanil via TCI. As part of the neuromonitoring, the bispectral index, spectral edge frequency (SEF), and median frequency (MF) will be recorded. Additionally, hemodynamic parameters will be recorded on a minute-by-minute basis.The primary objective is to describe BIS-guided adjustments of propofol during the anesthetic transition. Secondary objectives include describing interindividual variability in propofol titration, time to reach a BIS of 40-60, burst suppression patterns, SEF, MF, drug consumption, hemodynamic stability, and clinical adverse events. Statistical analysis will be primarily descriptive, examining correlations between BIS, propofol, and the minimum alveolar concentration (MAC) of sevoflurane.",[31,418,419],"Pediatric Anesthesia","Total Intravenous Anesthesia",[419,421,422,423,343,424,425,426,427,418,428],"TIVA","Bispectral Index","BIS","Sevoflurane","Eleveld","Target-Controlled Infusion","TCI","Anesthesia Transition",{"date":347,"type":36},{"date":431,"type":22},"2026-05-26",{"date":433,"type":22},"2027-03-28",{"name":435,"class":43},"Hospital de Clinicas José de San Martín",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":453,"locationsCount":4},"100638707","assessment-of-sevoflurane-consumption-during-general-anesthesia-with-a-low-fresh-gas-flow-rate-of-03-lmin-100638707","NCT07628231","Assessment of Sevoflurane Consumption During General Anesthesia With a Low Fresh Gas Flow Rate of 0.3 L\u002FMin","FGF 03","Inclusion Criteria:\n\n* Adult patients undergoing surgery under general anesthesia with mechanical ventilation\n\n  * Connected to a ventilator linked to the Carestaion software\n  * No refusal as indicated by a letter of consent\n\nExclusion Criteria:\n\n* Refusal to participate\n* Minor patients",{"count":444,"type":22},30,"Driven by industry demands and the need for anesthesia that consumes fewer resources (\"green anesthesia\"), manufacturers of anesthesia ventilators have developed closed-circuit ventilators. In a closed-circuit system, during the exhalation phase, gases are not released outside the ventilator into the atmosphere but are injected into the inspiratory limb of the circuit after being warmed and having CO2 removed. It is a closed loop. However, the loop is not completely closed because a very small stream of air is additionally injected into the inspiratory limb to limit the risk of hypoxia. This small stream of air is called \"Fresh Gas Flow\" or FGF.\n\nTo optimize this closed-loop recirculation, manufacturers have designed machines capable of minimizing the fresh gas flow. In the 2000s, machines operated with FGFs of 2 L\u002Fmin, dropping to flows as low as 0.5 L\u002Fmin by 2010. This low-flow regime allows for an 80% reduction in halogenated gas (sevoflurane) consumption while maintaining the same efficiency. Recently, even more sophisticated machines have been designed with FGFs of 0.3 L\u002Fmin. Some of these new machines will be commercially available on a large scale in 2026. As part of an industrial partnership, the Nîmes University Hospital has validated the post-CE marking of these machines for certain manufacturers (including General Electric); the post-CE marking allows the manufacturer to have access to usage data Given that this product has only recently been introduced to the market, very little data has been published on the use of sevoflurane in daily practice at very low FGF flow rates (0.3 to 0.5 L\u002Fmin).\n\nFor the past four months, the Nîmes University Hospital has had two CE-marked machines (GE, CS 850) capable of ventilating at flow rates of 0.3 L\u002Fmin. These machines are connected to software (Carestation Insight) that allows all anonymized ventilator data to be recorded independently of the users. This software has been in continuous use in 12 operating rooms since 2024 within our institution and has been the subject of numerous publications (see Ref. 19). All ventilation and sevoflurane data are continuously recorded and stored in a secure, anonymous cloud (Ref. 19).\n\nThe objective of this retrospective study is to analyze the database of sevoflurane consumption derived from the Carestation Insight software for patients who underwent general anesthesia with ventilation at FGF flow rates of 0.3 L\u002Fmin and to compare these data with our database of patients under anesthesia at flow rates of 0.5 to 2 L\u002Fmin, also derived from this same cloud.",[31],"2026-06-03",{"date":449,"type":36},"2026-06-04",{"date":451,"type":22},"2026-06",{"date":102,"type":22},{"name":454,"class":43},"Centre Hospitalier Universitaire de Nīmes",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":463,"enrollmentInfo":464,"targetDuration":4,"studyType":55,"phases":465,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":44},"100570083","early-phase-1-nitrous-oxide-neuroimaging-100570083","NCT06702631","Nitrous Oxide Neuroimaging","Functional MRI of Nitrous Oxide Inhalation in Volunteer Subjects","NONI","Inclusion Criteria:\n\n* have none of the specific exclusion criteria\n* have a valid email address and valid phone number throughout the study\n* free from any non-MRI compatible implants\n\nExclusion Criteria:\n\n* are pregnant or attempting to conceive\n* body mass index (BMI) \\> 35\n* significant memory impairment or hearing loss\n* sleep apnea\n* chronic pain or frequently taking pain medication (including tramadol)\n* any severe or poorly-controlled medical problem (hypertension, diabetes)\n* neurologic or psychiatric disease, including anxiety, and depression\n* severe cardiac disease\n* history of methylenetetrahydrofolate reductase (MTHFR) deficiency or variant mutation, as assessed by personal report\n* recent ear or eye surgery\n* being claustrophobic\n* have metal implants or non-removable metal piercings\n* having a history of adverse reaction to anesthetics\n* daily alcohol or heavy alcohol use; history of alcohol abuse\n* current daily smoker\n* regular or recent marijuana use (including prescribed\u002Fmedical marijuana)\n* illicit drug use, i.e., street drugs\n* regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids","59 Years",{"count":174,"type":22},[466],"EARLY_PHASE1","The purpose of this study is to determine the effects of acute pain on long-term memory and conditioned physiologic responses in the presence and absence of low dose nitrous oxide. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena. The study will occur over 2 visits and involves no long-term follow up.",[31,469,470],"Pain","Amnesia","2026-06-02",{"date":449,"type":36},{"date":474,"type":36},"2025-01-13",{"date":476,"type":22},"2026-09-01",{"name":478,"class":43},"Keith M Vogt",{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":55,"phases":489,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":499,"leadSponsor":501,"locationsCount":44},"100638552","phase-2-effect-of-vasopressin-versus-norepinephrine-on-post-operative-mean-pulmonary-arterial-pressure-following-pulmonary-endarterectomy-surgery-100638552","NCT07614438","Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery,","Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery, a Randomized Open Label Trial","VANOPE","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patient scheduled for pulmonary endarterectomy surgery;\n* In women of childbearing potential: negative serum pregnancy test and use of adequate contraception;\n* Affiliation to the French social care service;\n* Patient able to understand and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Emergency surgery;\n* Mesenteric ischemia and\u002For acute coronary syndrome within the month preceding the intervention;\n* Patients with documented mesenteric artery stenosis;\n* Impossibility to insert the pulmonary artery catheter (anatomical or technical issue);\n* Preoperative administration of norepinephrine and\u002For inotropic drugs (dobutamine, isoproterenol, epinephrine) or patients assisted by veno-venous or veno-arterial ECMO before surgery;\n* Known allergy to the active substance vasopressin or to any of its excipients;\n* Concomitant coronary bypass procedure or other combined surgery (i.e. valve replacement);\n* mPAP\\\u003C25 mmHg on preoperative right heart catheterization;\n* Patient with preoperative natremia below 130 mol\u002FL;\n* Patient participating to another interventional clinical trial;\n* For females only: documented pregnancy or lactation;\n* Patient under tutorship, curatorship or legal protection;\n* Patient deprived of liberty.",{"count":488,"type":22},90,[490],"PHASE2","Chronic thromboembolic pulmonary hypertension (CTEPH), one of the leading causes of pulmonary hypertension (PH), is caused by the chronic obstruction of the pulmonary arteries following episode of pulmonary embolism. It is the only cause of PH which is accessible to a potential curative surgical treatment: the pulmonary endarterectomy (PEA). Because of their underlying disease (pulmonary hypertension and potential right heart dysfunction), anesthesia should be performed cautiously. Perioperative hemodynamic management often requires the administration of a vasopressor to maintain the arterial pressure above a specific threshold of 65 mmHg.\n\nLow dose of vasopressin increases systemic arterial pressure with minimal effects on the pulmonary circulation. This profile suggests that vasopressin may be an ideal agent for vasopressor support in the high-risk population of patients with pulmonary hypertension.\n\nTo date, there is no data on the use of vasopressin in patient undergoing PEA surgery. The interesting properties of vasopressin - specifically, its ability to increase systemic arterial resistance while having a low impact on pulmonary resistance and offering potential renal protective effects - are highly advantageous in the specific subset of patient scheduled for PEA.\n\nThe investigators aim to conduct a randomized single center open label study to compare the effect of vasopressin compared to norepinephrine on mean pulmonary artery pressure after PEA surgery.\n\nThe primary objective of this study is to determine whether the use of vasopressin compared to norepinephrine decrease the mean pulmonary artery pressure after PEA surgery.\n\nParticipation to the study involves follow up at day 30 following surgery.",[31,493,494,495],"Pulmonary Hypertension","Chronic Pulmonary Thromboembolism","Vasopressor","2026-05-29",{"date":471,"type":36},{"date":100,"type":22},{"date":500,"type":22},"2028-09-01",{"name":502,"class":43},"Fondation Hôpital Saint-Joseph",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":510,"enrollmentInfo":511,"targetDuration":4,"studyType":55,"phases":513,"briefSummary":514,"conditions":515,"keywords":517,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":44},"100632730","light-and-anesthesia-100632730","NCT07517484","Light and Anesthesia","Effects and Mechanisms of Ambient Light Intensity on the Depth of General Anesthesia","Inclusion Criteria:\n\n* a. Age between 18 and 65 years, regardless of gender;\n* b. ASA physical status I-II;\n* c. 18.5 ≤ BMI ≤ 28;\n* d. Signed written informed consent.\n\nExclusion Criteria:\n\n* a. Blindness or history of photosensitivity disorders;\n* b. Patients requiring medication for sleep, or with a history of sleep disorders;\n* c. Presence of neurological diseases;\n* d. Pregnancy;\n* e. Severe hepatic or renal dysfunction;\n* f. History of anesthetic drug abuse or alcohol abuse;\n* g. History of adverse anesthesia events (difficult airway, allergy to anesthetic agents).","64 Years",{"count":512,"type":22},66,[57],"The objective of this clinical trial is to investigate the effect of light exposure on sedation depth during general anesthesia.The primary research questions this study aims to address include:\n\nDoes light condition affect the dosage of anesthetic medications during anesthesia? By what mechanism does light exposure exert an influence on anesthesia? Participants will be randomly allocated to either the light-shielded group or the non-light-shielded group.Patients in the light-shielded group will wear an eye shield during anesthesia.\n\nThe following data will be recorded for all patients:\n\nInduction drug dosage Induction time Intraoperative anesthetic dosage Emergence time",[516,31,334],"Light",[518,394,519],"light","sedation depth","2026-05-27",{"date":496,"type":36},{"date":523,"type":36},"2025-10-03",{"date":33,"type":22},{"name":526,"class":43},"Peking University People's Hospital",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":536,"conditions":537,"keywords":539,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":44},"100639659","minimally-invasive-hemodynamic-monitoring-in-cardiac-ablation-100639659","NCT07603765","Minimally Invasive Hemodynamic Monitoring in Cardiac Ablation","Prospective Clinical Study of Minimally Invasive Hemodynamic Monitoring Outcomes in Cardiac Ablation Procedures","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients scheduled for cardiac catheter ablation in the electrophysiology laboratory\n* Indication for ablation confirmed by a cardiologist\n* Ability to provide written informed consent\n* Planned invasive arterial blood pressure monitoring during the procedure\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent\n* Failure to identify arrhythmogenic focus leading to cancellation of ablation procedure\n* Severe hemodynamic instability prior to procedure\n* Contraindication to invasive arterial catheterization\n* Incomplete hemodynamic data acquisition\n* Pregnancy",{"count":535,"type":22},27,"This prospective observational clinical study aims to evaluate the clinical utility of Pressure Recording Analytical Method (PRAM)-based minimally invasive hemodynamic monitoring in patients undergoing cardiac ablation procedures. The study will be conducted in the cardiac catheterization laboratory of Istanbul University-Cerrahpaşa Cardiology Institute and will include 27 adult patients scheduled for catheter ablation. Written informed consent will be obtained from all participants, and the study will adhere to the principles of the Declaration of Helsinki.",[538,31],"Cardiac Arrythmias",[540,541,542,543,544],"catheter ablation","anesthesiology","conscious Sedation","deep sedation","hemodynamic monitoring","2026-05-21",{"date":547,"type":36},"2026-05-22",{"date":549,"type":36},"2026-04-30",{"date":551,"type":22},"2026-12-15",{"name":553,"class":43},"Istanbul University - Cerrahpasa",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":55,"phases":564,"briefSummary":565,"conditions":566,"keywords":572,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":587},"100577740","phase-4-the-choice-of-vasopressor-to-prevent-postoperative-acute-kidney-injury-after-major-non-cardiac-surgery-100577740","NCT06802224","The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery","Norepinephrine vs Phenylephrine as the First-line Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-cardiac Surgery","VEGA-2","Inclusion Criteria:\n\n* Age 18 years or older\n* Surgery under general anesthesia with a surgery duration of 2 hours or more\n* Received intravenous vasopressors during surgery\n\nExclusion Criteria:\n\n* Cardiac surgery\n* Extra-corporeal membrane oxygenation\n* Organ transplantation\n* Obstetric procedures\n* Procedures on the kidney\n* Outpatient procedures\n* Already receiving NE or PE or inotropes before induction of anesthesia (at the time of anesthesia start)\n* American Society of Anesthesiologists physical status classification 5 or 6\n* Patient for whom a local protocol recommends a specific first line vasopressor\n* Most recent documented estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73m\\^2 or preoperative renal replacement therapy within 60 days before surgery\n* Patients who do not have a preoperative creatinine value within 60 days before surgery\n* Alive patients who do not have a postoperative creatinine value",{"count":563,"type":22},18000,[149],"Low blood pressure, also known as hypotension, is very common during major surgery under general anesthesia. Prolonged or severe hypotension can lead to complications such as kidney injury after surgery that slow down patient recovery. Anesthesiologists commonly administer medications called vasopressors to treat low blood pressure during surgery. These medications help raise the blood pressure back up to a safe range. Two vasopressor medications are commonly used for this purpose: norepinephrine and phenylephrine. Each of these medications has slightly different effects on the heart and blood vessels (cardiovascular system). It remains unknown which of these standard medications is better for treating low blood pressure during surgery. The goal of this clinical trial is to determine which of these two medications is better at preventing injury to the kidneys after major noncardiac surgery as well as other complications such as heart problems. Major surgeries are defined as those lasting at least two hours under general anesthesia. This trial will randomize about ten centers in North America to use either norepinephrine or phenylephrine as the primary medication to treat low blood pressure in adults undergoing major noncardiac surgery. Each hospital will prioritize one of the drugs each month, and the assigned drug will rotate each month at each hospital. No further participant involvement will be required as de-identified data are collected as part of standard medical care.",[31,567,568,569,570,571,495],"Surgery With General Anesthesia","Noncardiac Surgery","Hypotension During Surgery","Acute Kidney Injury (AKI)","Myocardial Injury After Noncardiac Surgery (MINS)",[573,574,575,576,577,578],"Norepinephrine","Phenylephrine","Major adverse kidney events","Pragmatic","Cluster randomized","Crossover","2026-05-20",{"date":431,"type":36},{"date":582,"type":36},"2025-04-01",{"date":584,"type":22},"2028-07",{"name":586,"class":43},"University of California, San Francisco",10,{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":17,"sex":18,"minAge":85,"maxAge":595,"enrollmentInfo":596,"targetDuration":4,"studyType":55,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":603,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":607,"locationsCount":44},"100539413","end-tidal-carbon-dioxide-concentration-and-depth-of-anesthesia-in-children-100539413","NCT06303518","End Tidal Carbon Dioxide Concentration and Depth of Anesthesia in Children","Effects of End Tidal Carbon Dioxide Concentration on Depth of Anesthesia in Children Undergoing Total Intravenous Anesthesia","Inclusion Criteria:\n\n* Children aged 3 - 11 years undergoing non- or minimally-stimulating elective procedures, defined as anesthesia without skin incision or painful manipulation (e.g., non-invasive imaging, auditory brainstem response testing), middle ear surgery, surgery with effective local or regional anesthesia before surgical incision (e.g dental procedures with local anesthetic infiltration, urology with regional block).\n* American Society of Anesthesiologists (ASA) physical status I and II\n* TIVA technique appropriate throughout induction and maintenance of anesthesia\n* Controlled ventilation via endotracheal tube\n* Anticipated surgical time ≥ 90 minutes: to allow time for anesthetic induction and subsequent testing and washout periods at all three EtCO2 levels.\n\nExclusion Criteria:\n\n* Need for inhalational induction of anesthesia\n* Sedative premedication\n* Use of ketamine intraoperatively\n* Unable to place BIS electrodes due to surgical site or other contraindications (e.g., MRI)\n* Allergy to study drugs (propofol, remifentanil, lidocaine)\n* Depression of conscious level for any reason\n* BMI \\\u003C5th or \\>95th centile for age\n* History of obstructive or central sleep apnea\n* Known or suspected raised intracranial pressure\n* Recent or historical traumatic brain injury","11 Years",{"count":597,"type":22},100,[57],"Carbon Dioxide (CO2) is a by-product of metabolism and is removed from the body when we breathe out. High levels of CO2 can affect the nervous system and cause us to be sleepy or sedated. Research suggests that high levels of CO2 may benefit patients who are asleep under anesthesia, such as by reducing infection rates, nausea, or recovery from anesthesia . CO2 may also reduce pain signals or the medication required to keep patients asleep during anesthesia; this has not been researched in children.\n\nDuring general anesthesia, anesthesiologists keep patients asleep with anesthetic gases or by giving medications into a vein. These drugs can depress breathing; therefore, an anesthesiologist will control breathing (ventilation) with an artificial airway such as an endotracheal tube. Changes in ventilation can alter the amount of CO2 removed from the body. The anesthesiologist may also monitor a patient's level of consciousness using a 'Depth of Anesthesia Monitor' such as the Bispectral Index (BIS), which analyzes a patient's brain activity and generates a number to tell the anesthesiologist how asleep they are.\n\nThe investigator's study will test if different levels of CO2 during intravenous anesthesia are linked with different levels of sedation or sleepiness in children, as measured by BIS. If so, this could reduce the amount of anesthetic medication the child receives. Other benefits may be decreased medication costs, fewer side effects, and a positive environmental impact by using less disposable anesthesia equipment.",[31,601,602],"Hypercapnia","Hypocapnia",{"date":547,"type":36},{"date":605,"type":36},"2024-06-25",{"date":40,"type":22},{"name":608,"class":43},"University of British Columbia",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":617,"targetDuration":4,"studyType":55,"phases":619,"briefSummary":620,"conditions":621,"keywords":624,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":44},"100639499","real-time-acute-kidney-injury-perioperative-prediction-clinical-trial-100639499","NCT07604662","Real-Time Acute Kidney Injury Perioperative Prediction Clinical Trial","Prediction of Acute Kidney Injury (AKI) After Surgery: A Pragmatic Three-Arm Cluster-Randomized Trial","ML-AKI","Inclusion Criteria:\n\n* Adults ≥18 years undergoing non-obstetric surgery at UCSF.\n* Inpatient cases with expected overnight stay.\n* Baseline eGFR ≥15 mL\u002Fmin\u002F1.73 m².\n* Managed by an attending anesthesiologist randomized to one of three arms (CRNAs\u002Fresidents follow attending).\n* Data available in the UCSF EHR for risk scoring and outcomes.\n\nExclusion Criteria:\n\n* Obstetric procedures.\n* Chronic dialysis patients.\n* Kidney transplant recipients.\n* Cases without baseline creatinine\u002FeGFR or missing essential EHR elements needed for scoring\u002Foutcomes (operational exclusions).\n* Outpatient procedures without expected overnight stay.",{"count":618,"type":22},25518,[57],"This investigator-initiated, pragmatic trial evaluates whether displaying a machine learning (ML)- derived perioperative AKI risk score-alone or paired with an interruptive Best\u002FOur Practice Advisory (BPA\u002FOPA)-improves kidney-protective care and reduces kidney injury after non-obstetric surgery at UCSF. Approximately 75-100 attending anesthesiologists (clusters) are randomized 1:1:1 to: (a) Control (risk score hidden), (b) Score Only (visible preoperative AKI risk probability with passive KDIGO bundle recommendation), or (c) Score + BPA (visible risk plus interruptive KDIGO prompt for high-risk patients). CRNAs\u002Fresidents follow their attending' s assignment. Adult inpatients (age ≥18) with expected overnight stay and eGFR ≥15 mL\u002Fmin\u002F1.73 m² are included; obstetrics, chronic dialysis, and kidney transplant patients are excluded. The underlying preoperative model was prospectively validated at UCSF and outperforms anesthesiologist risk estimation reported in the literature. The model was reviewed and approved by the AI Oversight Committee at UCSF. Primary endpoint is the continuous change in serum creatinine (mg\u002FdL) from baseline to POD 1-2. Secondary outcomes include KDIGO-defined AKI, adherence to bundle elements (hemodynamics, balanced fluids, nephrotoxin avoidance, glycemic control), intraoperative hypotension time, fluid volumes, nephrotoxin exposure, perioperative hyperglycemia, length of stay, unplanned ICU transfer, readmission, dialysis, and in-hospital mortality. Data are obtained from the EHR; analysts are blinded. No direct subject interaction is planned; the investigators will request a waiver of patient consent. The study aims to demonstrate that ML-enabled, workflow-embedded decision support can safely and feasibly improve guideline concordant care and decrease early postoperative kidney injury.",[622,623,31],"Acute Kidney Injury","Surgery Complications",[622,625,626,627,628],"Surgical Outcomes","Machine Learning","Clinical Decision Support","Electronic Health Records","2026-05-19",{"date":547,"type":36},{"date":632,"type":22},"2026-10-15",{"date":634,"type":22},"2027-12-15",{"name":586,"class":43},{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":643,"enrollmentInfo":644,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":646,"conditions":647,"keywords":650,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":4},"100639213","elucidating-the-neural-correlates-of-anesthesia-induced-unconsciousness-in-neonates-100639213","NCT07601854","Elucidating the Neural Correlates of Anesthesia-induced Unconsciousness in Neonates","NeoNCC","Inclusion Criteria:\n\n* Full term neonates (37 - 42 weeks of gestational age)\n* Require general anesthesia\u002Fdeep sedation during their first 28 days of life because they require a surgery or a specific procedure (cardiac or non-cardiac)\n* Scheduled for propofol induction\n\nExclusion Criteria:\n\n* Neurological surgeries\n* Perinatal asphyxia\n* Evidence of neurological injury or pathology\n* Suspected brain malformations\n* Patients with metabolic or hemodynamic instability at the time of the surgery or procedure.","28 Days",{"count":645,"type":22},64,"This study will try to elucidate the neural responses of neonatal patients to surgery-level propofol infusions during induction and maintenance of anesthesia. The main objective is to elucidate the EEG patterns of neural activity that can reliably reflect the level of hypnotic depth in full term neonates undergoing propofol anesthesia based on the classification of EEG into states and the characterization of discrete neonatal EEG events.",[648,31,649],"Anesthesia Brain Monitor","Neonatal Surgery",[651,652,653,654,655],"neonatal anesthesia","propofol","brain monitoring","neonatal brain monitoring","neonatal brain states","2026-05-18",{"date":547,"type":36},{"date":659,"type":22},"2026-05-15",{"date":661,"type":22},"2029-05-15",{"name":663,"class":43},"Pontificia Universidad Catolica de Chile",{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":668,"acronym":669,"eligibilityCriteria":670,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":671,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":673,"conditions":674,"keywords":676,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":681,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":44},"100637996","perioperative-predictive-value-of-physical-activity-on-short--and-long-term-morbidity-and-mortality-100637996","NCT07603622","Perioperative Predictive Value of Physical Activity on Short- and Long-term Morbidity and Mortality","PeriopPrePA","Inclusion Criteria:\n\n* Adult patients (equal to or over 18 years) undergoing elective non-cardiac surgery at the two study sites, Karolinska University Hospital Solna and Karolinska University Hospital Huddinge\n\nExclusion Criteria:\n\n* Patients under the age of 18, transplant, day surgery, acute surgery, anesthesia monitoring, brachy therapy and gamma knife interventions. In case of multiple surgeries, only the first will be included.",{"count":672,"type":22},50000,"Over 300 million surgeries are performed globally every year. Complications after surgery - infections, cardiovascular conditions, postoperative pulmonary complications and renal impairment - affect survival and quality of life.\n\nAge and co-morbidity are unmodifiable factors, contributing to increased risk of these perioperative complications. However, a modifiable risk factor is physical activity. This study aims to test if self reported physical activity has added predicted value, beyond established risk factors, for predicting perioperative morbidity and mortality.",[31,675,623],"Surgery",[677,678,679,680],"Perioperative medicine","Outcome","Mortality","Morbidity",{"date":547,"type":36},{"date":683,"type":22},"2026-05-01",{"date":685,"type":22},"2026-11-30",{"name":687,"class":43},"Karolinska Institutet"]